{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:25:30Z","timestamp":1787840730083,"version":"build-2784847793"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"\n Background:<\/jats:title>\n The long-term efficacy of low-dose aspirin for primary prevention of cardiovascular (CV) events in postmenopausal women with type-2 diabetes is controversial. Therefore, it is recommended only on an individual basis, recommendation of grade C.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n We enrolled 275 consecutive postmenopausal women with type-2 diabetes, without an increased bleeding risk and without preexisting CV disease as coronary artery disease, stroke, and peripheral vascular disease, but with a high risk assessed by score >10%, aged 60\u201369 years. All were receiving aspirin (75\u2013100 mg daily), aspirin group (AG). 170 postmenopausal women with type-2 diabetes and without preexisting cardiovascular (CV) disease, but not on aspirin treatment, despite a high risk assessed by score >10%, were control group (CG). Mean age was 66 \u00b1 4 years for AG and 65 \u00b1 7 years for CG. Our goal was to identify the prevalence of low-dose aspirin prescriptions in these populations according to different clinical conditions.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Women with only high risk were 41\/275 (15%) on AG and 72\/170 (42.3%) on CG,\n Chi-squared 41, Odds ratio 0.2, c.i. 95%, P<\/jats:italic>\n < 0.0001. Women affected by metabolic syndrome were 105\/275 (38.1%) on AG and 47\/170 (27.6%) on CG,\n Chi-squared 5.1, Odds ratio 1.6, c.i. 95%, P<\/jats:italic>\n < 0.02. Women affected by metabolic cardiomyopathy were 111\/275 (40.3%) on AG and 44\/170 (25.9%) on CG,\n Chi-squared 8, Odds ratio 1.8, c.i. 95%, P<\/jats:italic>\n < 0.004. Women affected by diabetic cardiomyopathy were 18\/275 (6.6%) on AG and 7\/170 (4.2%) on CG,\n Chi-squared 1.2, Odds ratio 16, c.i. 95%<\/jats:italic>\n ,\n P<\/jats:italic>\n < 0.2 n.s.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Low-dose aspirin in our population is prescribed preferentially in postmenopausal women with type-2 diabetes when affected by metabolic syndrome or metabolic cardiomyopathy, at the opposite women with only high risk have lower chance to receive aspirin.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijpvm.ijpvm_365_19","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T08:29:49Z","timestamp":1716884989000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Low-dose Aspirin for Primary Prevention of Cardiovascular Events in Postmenopausal Women with Type-2 Diabetes: The Prescriptive Approach in the Real World"],"prefix":"10.4103","volume":"12","author":[{"given":"Maria","family":"Maiello","sequence":"first","affiliation":[{"name":"ASL Brindisi, Department of Cardiology Equipe, District of Brindisi, Brindisi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annagrazia","family":"Cecere","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Section, Department of Emergency and Organ Transplantation (Deto), University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapaola","family":"Zito","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Section, Department of Emergency and Organ Transplantation (Deto), University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Matteo","family":"Ciccone","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Section, Department of Emergency and Organ Transplantation (Deto), University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Palmiero","sequence":"additional","affiliation":[{"name":"ASL Brindisi, Department of Cardiology Equipe, District of Brindisi, Brindisi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"R1-20250812","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJM200004063421408","article-title":"Coronary heart disease in patients with diabetes","volume":"342","author":"Haffner","year":"2000","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"R2-20250812","doi-asserted-by":"crossref","first-page":"C3","DOI":"10.2337\/diacare.21.3.C3","article-title":"Epidemiology of type 2 diabetes: Risk factors","volume":"21","author":"Haffner","year":"1998","journal-title":"Diabetes Care"},{"key":"R3-20250812","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.1992.03490100090033","article-title":"Early treatment diabetic retinopathy study report 14. ETDRS investigators","volume":"268","year":"1992","journal-title":"JAMA"},{"key":"R4-20250812","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"R5-20250812","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"R6-20250812","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrendo.2010.169","article-title":"Aspirin for primary prevention of cardiovascular disease in diabetes mellitus","volume":"6","author":"Pignone","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"R7-20250812","doi-asserted-by":"crossref","first-page":"b4531","DOI":"10.1136\/bmj.b4531","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes: Meta-analysis of randomised controlled trials","volume":"339","author":"De Berardis","year":"2009","journal-title":"BMJ"},{"key":"R8-20250812","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.diabres.2009.09.029","article-title":"Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis","volume":"87","author":"Zhang","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"R9-20250812","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.2337\/dc09-1297","article-title":"Aspirin for the primary prevention of cardiovascular events: A systematic review and meta-analysis comparing patients with and without diabetes","volume":"32","author":"Calvin","year":"2009","journal-title":"Diabetes Care"},{"key":"R10-20250812","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"R11-20250812","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: A systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"R12-20250812","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1741-7015-5-29","article-title":"The influence of gender on the effects of aspirin in preventing myocardial infarction","volume":"5","author":"Yerman","year":"2007","journal-title":"BMC Med"},{"key":"R13-20250812","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","article-title":"Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials","volume":"295","author":"Berger","year":"2006","journal-title":"JAMA"},{"key":"R14-20250812","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: Analysis of individual patient data from randomised trials","volume":"392","author":"Rothwell","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"R15-20250812","doi-asserted-by":"crossref","first-page":"834","DOI":"10.7326\/0003-4819-137-10-200211190-00013","article-title":"Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recomendations and rationale","volume":"137","year":"2002","journal-title":"Ann Intern Med"},{"key":"R16-20250812","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/01.CIR.0000020190.45892.75","article-title":"AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American heart association science advisory and coordinating committee","volume":"106","author":"Pearson","year":"2002","journal-title":"Circulation"},{"key":"R17-20250812","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000114834.85476.81","article-title":"Evidence-based guidelines for cardiovascular disease prevention in women","volume":"109","author":"Mosca","year":"2004","journal-title":"Circulation"},{"key":"R18-20250812","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"R19-20250812","doi-asserted-by":"crossref","first-page":"e90286","DOI":"10.1371\/journal.pone.0090286","article-title":"Aspirin for primary prevention of cardiovascular events: Meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status","volume":"9","author":"Xie","year":"2014","journal-title":"PLoS One"},{"key":"R20-20250812","doi-asserted-by":"crossref","first-page":"NP1","DOI":"10.1177\/2047487316653709","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for cardiovascular prevention and rehabilitation (EACPR)","volume":"23","author":"Piepoli","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"R21-20250812","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.dsx.2016.08.003","article-title":"Metabolic syndrome and its components in postmenopausal women living in southern Italy, Apulia region","volume":"11","author":"Maiello","year":"2017","journal-title":"Diabetes Metab Syndr"},{"key":"R22-20250812","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"R23-20250812","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jacc.2014.03.049","article-title":"Aspirin therapy in primary cardiovascular disease prevention: A position paper of the European society of cardiology working group on thrombosis","volume":"64","author":"Halvorsen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R24-20250812","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","article-title":"Alternate-day, low-dose aspirin and cancer risk: Long-term observational follow-up of a randomized trial","volume":"159","author":"Cook","year":"2013","journal-title":"Ann Intern Med"},{"key":"R25-20250812","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"R26-20250812","first-page":"1832","article-title":"17 beta-estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells","volume":"80","author":"Mikkola","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-20250812","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0741-5214(98)70016-3","article-title":"Estrogen improves endothelial function","volume":"27","author":"Arora","year":"1998","journal-title":"J Vasc Surg"},{"key":"R28-20250812","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJM199906103402306","article-title":"The protective effects of estrogen on the cardiovascular system","volume":"340","author":"Mendelsohn","year":"1999","journal-title":"N Engl J Med"},{"key":"R29-20250812","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1160\/TH10-04-0232","article-title":"Impact of race and gender on antithrombotic therapy","volume":"104","author":"Capodanno","year":"2010","journal-title":"Thromb Haemost"},{"key":"R30-20250812","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1161\/01.CIR.91.11.2742","article-title":"Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses","volume":"91","author":"Ajayi","year":"1995","journal-title":"Circulation"},{"key":"R31-20250812","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R32-20250812","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1160\/TH04-09-0608","article-title":"Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The women's health initiative observational study","volume":"93","author":"Langer","year":"2005","journal-title":"Thromb Haemost"},{"key":"R33-20250812","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"R38-20250812","doi-asserted-by":"crossref","first-page":"e71522","DOI":"10.1371\/journal.pone.0071522","article-title":"Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: A systematic review and meta-analysis","volume":"8","author":"Ye","year":"2013","journal-title":"PloS One"},{"key":"R39-20250812","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamaoncol.2015.6396","article-title":"Population-wide impact of long-term use of aspirin and the risk for cancer","volume":"2","author":"Cao","year":"2016","journal-title":"JAMA Oncol"},{"key":"R40-20250812","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s12471-010-0841-y","article-title":"Gender differences in coronary heart disease","volume":"18","author":"Maas","year":"2010","journal-title":"Neth Heart J"},{"key":"R41-20250812","first-page":"1","article-title":"Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: A systematic review and overview of reviews","volume":"17","author":"Sutcliffe","year":"2013","journal-title":"Health Technol Assess Winch Engl"},{"key":"R42-20250812","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21037\/atm.2016.06.33","article-title":"Epidemiology of coronary heart disease and acute coronary syndrome","volume":"4","author":"Sanchis-Gomar","year":"2016","journal-title":"Ann Transl Med"}],"container-title":["International Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.IJPVM_365_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:27:50Z","timestamp":1787837270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.IJPVM_365_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_365_19","relation":{},"ISSN":["2008-7802","2008-8213"],"issn-type":[{"value":"2008-7802","type":"print"},{"value":"2008-8213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"2019-12-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}